Hennion & Walsh Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Hennion & Walsh Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,385	Closed	-$2.26M	–	843
2023 Q1	$2.26M	Sell	16,385 -561	-3%	-$72.8K	0.14%	190
2022 Q4	$2.2M	Buy	16,946 +2,142	+14%	+$248K	0.14%	193
2022 Q3	$1.64M	Sell	14,804 -205	-1%	-$20.7K	0.11%	223
2022 Q2	$1.13M	Sell	15,009 -223	-1%	-$16.4K	0.07%	287
2022 Q1	$1.19M	Buy	15,232 +311	+2%	+$23.8K	0.06%	303
2021 Q4	$1.34M	Buy	14,921 +933	+7%	+$79.8K	0.07%	299
2021 Q3	$1.29M	Buy	13,988 +4,790	+52%	+$369K	0.07%	304
2021 Q2	$715K	Buy	+9,198	New	+$697K	0.04%	439

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Hennion & Walsh Asset Management's SRPT Position: Q2 2023 in Review

Hennion & Walsh Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2023, closing a stake of 16,385 shares — an estimated $2.26M sold.

Hennion & Walsh Asset Management first reported a position in SRPT in Q2 2021 and held it in 8 quarters. The position peaked at $2.26M in Q1 2023. 404 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

Hennion & Walsh Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 16,385 Sarepta Therapeutics shares in Q2 2023, an estimated $2.26M.
Hennion & Walsh Asset Management first reported a position in Sarepta Therapeutics in Q2 2021 and held it in 8 quarters.
Hennion & Walsh Asset Management's Sarepta Therapeutics position peaked at $2.26M in Q1 2023.
404 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.